New practice guidelines for the treatment of opioid use disorder (OUD) with buprenorphine, only announced roughly a month ago, have been canceled by the Biden administration—but an update to the regulations is still a possibility.
The guidelines, announced Jan. 14, 2021, by the outgoing Trump administration, were to relax the Health and Human Services–mandated “X-waiver” requirements and allow any office-based, Drug Enforcement Administration–licensed physician to